Nerve-sparing techniques will undoubtedly occupy a large part of the testis cancer surgeon's armamentarium in the future. More liberal application of such techniques will be seen after chemotherapy as the criteria for patient selection are refined. With better identification of risk factors for relapse, the employment of proactive methods such as nerve-sparing retroperitoneal surgery with or without adjuvant or primary chemotherapy promises to improve patients' options on the basis of solid long-term results, including risk-benefit and cost-benefit analyses.
|Original language||English (US)|
|Number of pages||9|
|Journal||Urologic Clinics of North America|
|State||Published - Jan 1 1993|
ASJC Scopus subject areas